News Search Results
Dec 11, 2024, 09:00 ET Negev Labs Emerges from Stealth with Announcement of Alexander Shulgin Research Institute Licensing Agreement, Acquisition of Beckley Psytech Development Program and R&D Collaboration with Hadassah Brain Labs Center for Psychedelic Research
originally discovered by famed chemist Alexander (Sasha) Shulgin Acquisition of Beckley Psytech's Ophthalmology development program aligns with Negev's mission to develop the full therapeutic potential of neuroplastogens Negev Labs and
More news about: Negev Labs
Dec 11, 2024, 06:00 ET IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
Speakers Carol Shields, M.D., Chief, Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson UniversityAmy Schefler, M.D., Partner at Retina Consultants of Texas,
More news about: IDEAYA Biosciences, Inc.
Dec 10, 2024, 09:29 ET UMass Memorial Health Integrates AEYE Health's AEYE-DS Autonomous AI Screening for Diabetic Eye Care into EMR System
solution, into UMMH's EMR system. This integration intends to enhance diabetic eye care by improving screening processes and adherence, reduce ophthalmology wait times, and boost quality and performance markers.
More news about: AEYE Health
Dec 10, 2024, 08:15 ET Emmes adds new role as it looks to expand government footprint
companies throughout the world. The company has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, and neuroscience. Today, we are part of the Emmes Group, helping transform the future of clinical research. Learn more at
More news about: Emmes
Dec 09, 2024, 03:00 ET Dr. James G. Fujimoto of U.S. Awarded 45th Honda Prize for His Team's Development of Optical Coherence Tomography (OCT): Real-time Tissue Imaging Technology
vessels. He also commercialized the world's first ophthalmic OCT aiming to promote its widespread use. Today, OCT has found applications not only in ophthalmology and cardiology, but also in the early detection of diabetic and neurological diseases, industrial non-destructive testing equipment, fingerprint
More news about: Honda Foundation
Dec 08, 2024, 19:00 ET Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced updated Phase 1 study results of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced pancreatic
More news about: Innovent Biologics
Dec 06, 2024, 10:21 ET BASCOM PALMER RECEIVES MULTIMILLION DOLLAR AWARD TO SUPPORT FUNCTIONAL WHOLE-EYE TRANSPLANT
Daniel Pelaez, Ph.D., associate professor of ophthalmology at the Miller School and a co-principal investigator of the award. Preparing for Eye Transplant Joining Pelaez as a co-principal
More news about: University of Miami Miller School of Medicine
Dec 06, 2024, 07:00 ET Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. Lead development candidate laru-zova (AGTC-501), is a gene therapy program currently being investigated for the treatment of XLRP,
More news about: Beacon Therapeutics
Dec 06, 2024, 04:30 ET Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
highly qualified doctors and staff in different specialties including internal medicine, general surgery, pediatrics, neurology/ neurosurgery, ophthalmology and pediatrics. Besides the regular outpatient and surgical facilities, the ICU and emergency services provide round-the-clock medical care. The
More news about: Microland Foundation
Dec 05, 2024, 06:00 ET NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
more than 100 countries, engaged in research, development, registration, and commercialization of drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas including pediatrics, gynecology, and gastroenterology. NTC offers more than 200 partners innovative and high quality
More news about: NTC Srl
Dec 05, 2024, 06:00 ET NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
more than 100 countries, engaged in research, development, registration, and commercialization of drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas including pediatrics, gynecology, and gastroenterology. NTC offers more than 200 partners innovative and high quality
More news about: NTC Srl
Dec 04, 2024, 17:44 ET ZEISS Industrial Quality Solutions Transforms its Go-to-Market-Strategy in Canada to Drive Customer Excellence
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Dec 04, 2024, 13:00 ET Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO
of the Year Award in 2021. Dr. Naageshwaran's research has been featured at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT) and American Association for Cancer Research (AACR).
More news about: Franklin Biolabs
Dec 04, 2024, 10:14 ET Shaping the Future of Veterinary Medicine: VMX 2025 to Advance Health Care for Beloved Pets, Wildlife and Species Across the Animal Kingdom - from Dogs and Cats to Kangaroos and Honey Bees
of life for pets with serious health challenges. Ron Ofri, DVM, PhD, an expert in veterinary ophthalmology, will challenge myths around animal vision with his session, "Do Dogs Really See in Black & White? Facts and Myths About Animal
More news about: North American Veterinary Community
Dec 04, 2024, 09:15 ET The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities Issued on behalf of Avant Technologies Inc.
are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care. The results of this pilot program will be the basis for developing the model beyond
More news about: USA News Group
Dec 03, 2024, 19:00 ET Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13)，jointly announce
More news about: Innovent Biologics
Dec 03, 2024, 09:00 ET Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnologies, Inc.
Dec 03, 2024, 08:51 ET Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnnologies, Inc.
Dec 02, 2024, 17:33 ET Active Pharmaceutical Ingredients Market to Grow by USD 86.47 Billion (2024-2028), Driven by Evolving API Manufacturing, with AI Driving Market Transformation - Technavio
dominate, but large molecule APIs for Prescription Drugs in Cardiology, CNS Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Nephrology, Ophthalmology, and other therapeutic applications are gaining popularity. Captive API Manufacturers and Merchant API Manufacturers must navigate these challenges
More news about: Technavio
Dec 02, 2024, 10:04 ET Savor the Day with a Brunch to Behold: Music, Mimosas, & a Mission
than two decades, Dr. Brimer spent her career advancing the science of diagnosing and treating dry eye disease. Brimer has been featured in the Ophthalmology Times, Global Newswire and television and speaks nationally and internationally. For more information about dry eye disease and treatments visit
More news about: Hope In Sight
Dec 02, 2024, 06:45 ET Mallinckrodt Completes Divestiture of Therakos® Business
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Nov 28, 2024, 05:30 ET Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
to build a strong portfolio of innovative ophthalmology solutions." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary
More news about: Formosa Pharmaceuticals Inc.,
Nov 27, 2024, 23:05 ET Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the updated 2024 National Reimbursement Drug List (NRDL) now includes SINTBILO® (tafolecimab injection,
More news about: Innovent Biologics
Nov 27, 2024, 17:05 ET Biomaterials Market to Grow by USD 12.76 Billion (2024-2028) with Rising Musculoskeletal Disorders, Report with Market Evolution Powered by AI - Technavio
and minimally invasive procedures are key areas of focus. Key therapeutic areas include musculoskeletal disorders, neurological applications, and ophthalmology applications. Drug delivery systems using nanoparticles, microspheres, and hydrogels are gaining popularity. Biodegradable materials like polyglycolic
More news about: Technavio
Nov 25, 2024, 15:55 ET Medical Equipment Maintenance Market to Grow by USD 51.21 Billion (2024-2028), Driven by Focus on Preventive Maintenance, AI Redefining Market Landscape - Technavio
Medical Devices. Device types include Diagnostic Imaging Equipment, Dental Equipment, Endoscopic Devices, Surgical Equipment, Laboratory Equipment, Ophthalmology Equipment, Medical Lasers, Electrosurgical Equipment, Radiotherapy Devices, and Durable Medical Equipment. Service Providers offer various types
More news about: Technavio